# OnCo record tucatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tucatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tucatinib" ;
  schema:name "Tucatinib"@en ;
  schema:description "A HER2-selective pill that works in the brain, for HER2-positive breast cancer with brain metastases."@en ;
  schema:url <https://onco.cc/drugs/tucatinib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tucatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q25100690> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tucatinib>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (HER2)" ;
  schema:alternateName "Tukysa" ;
  onco:approval "US 2020: HER2+ metastatic breast cancer including brain metastases, with trastuzumab and capecitabine", "US 2023: HER2+ RAS-wild-type mCRC with trastuzumab", "US 2023: HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer that has progressed after fluoropyrimidine, oxaliplatin and irinotecan, with trastuzumab" ;
  onco:acceleratedApproval "US 2023-01-19: In combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive, unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy" ;
  onco:related <https://onco.cc/pairings/tucatinib-triplet-brain-mets/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/her2-amplified-colorectal/>, <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/cancers/her2-positive-breast-brain-metastases/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct04430738/>, <https://onco.cc/trials/nct05458674/>, <https://onco.cc/trials/nct04538742/>, <https://onco.cc/trials/nct06157892/>, <https://onco.cc/trials/nct06686394/>, <https://onco.cc/trials/nct05230810/>, <https://onco.cc/trials/nct05190445/>, <https://onco.cc/trials/nct04721977/>, <https://onco.cc/trials/nct04579380/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/mountaineer-03/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/>, <https://onco.cc/key-papers/paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016/> .